stockportfolio.pro
Stocks / ABUS vs JANX
ABUS vs JANX
Arbutus Biopharma Corporation and Janux Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arbutus Biopharma Corporation (ABUS) | Janux Therapeutics, Inc. (JANX) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $14.08M | $10.00M |
| Net income (latest FY) | $-33.50M | $-113.63M |
| Revenue growth (5y CAGR) | 15.3% | — |
| Net margin | -237.9% | -1136.3% |
| Return on equity | -43.7% | -11.9% |
| P/E ratio | 5.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABUS — free Open JANX — freeFrequently asked questions
Which is bigger, ABUS or JANX?
Arbutus Biopharma Corporation is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, ABUS or JANX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.